One could be forgiven for feeling the same way about the current world of drug delivery devices, with an increasingly ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Competition concerns are overblown; Viking's dual GLP-1/GIP agonist has competitive advantages over single-mechanism therapeutics, and concern regarding small-molecule candidates is as yet unfounded.

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist to reach the market, but has also benefitted from supply constraints from Novo Nordisk's GLP-1 agonist ...

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...

The prevalence of substance use disorders, such as opioid and alcohol use disorders, has created a significant public health ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.